Isis, Pfizer enter drug discover pact

NEW YORK (MarketWatch) -- Isis Pharmaceuticals
isis
said it would receive a $1 million technology access fee from Pfizer
PFE, +1.54%
as part of the companies' new multi-year agreement to identify ophthalmic disease treatments. Isis will also receive research funding and potential milestone payments. Isis shares closed Monday up 3 cents at $2.94 and Pfizer, a component of the Dow industrials, rose 18 cents to $28.76.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.